Apellis Pharmaceuticals, Inc. (APLS) NASDAQ
40.90
+0.03(+0.07%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
40.90
+0.03(+0.07%)
Currency In USD
| Previous Close | 40.87 |
| Open | 40.86 |
| Day High | 40.95 |
| Day Low | 40.85 |
| 52-Week High | 40.95 |
| 52-Week Low | 16.1 |
| Volume | 5.19M |
| Average Volume | 5.12M |
| Market Cap | 5.23B |
| PE | 227.22 |
| EPS | 0.18 |
| Moving Average 50 Days | 25.52 |
| Moving Average 200 Days | 23.9 |
| Change | 0.03 |
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
GlobeNewswire Inc.
Mar 02, 2026 12:00 PM GMT
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company’s board of directors as of March 1. Most recently, Dr. Dolsten served for more
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 23, 2026 12:00 PM GMT
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026,
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
GlobeNewswire Inc.
Feb 19, 2026 12:00 PM GMT
Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS)